

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appn. No. : *Continuation of 09/993,896*
Applicant : REDMOND et al.
Filed : Herewith
TC/A.U. : 1614
Examiner : J. Goldberg

Docket No. : **1194-282**
Customer No. : **6449**


Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Under the provisions of 37 C.F.R. §§ 1.56, 1.97 and 1.98, Applicant submits herewith copies of publications that the Office may wish to consider in examination of the subject application. The publications are listed on the attached form PTO-1449.

Respectfully submitted,

By 
George R. Repper
Attorney for Applicants
Registration No. 31,414
ROTHWELL, FIGG, ERNST & MANBECK, p.c.
Suite 800, 1425 K Street, N.W.
Washington, D.C. 20005
Telephone: (202)783-6040

INFORMATION DISCLOSURE STATEMENT BY APPLICANT				<i>Complete if Known</i>	
				Application Number	Continuation of 09/993,896
				Filing Date	Herewith
				First Named Inventor	REDMOND
				Group Art Unit	
				Examiner Name	
Sheet	1	of	2	Attorney Docket Number	1194-282

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code ² (if known)		
	1	6,479,481	B1	STENDEL et al.	11/12/2002

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee of Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T ⁶
		Office ³ Code	Number ⁴	Kind ⁵ (if known)			
	2	WO	92/00743	A1	Ed Geistlich Soehne AG fuer Chemische Industrie	01/23/1992	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code. ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached. AB indicates that only an English language abstract is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT				<i>Complete if Known</i>	
				Application Number	<i>Continuation of 09/993,896</i>
				Filing Date	Herewith
				First Named Inventor	REDMOND
				Group Art Unit	
				Examiner Name	
Sheet	2	of	2	Attorney Docket Number	1194-282
OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			T ²
	3	BRAUMANN, C., et al. , "The Influence of Intraoperative Intravenous and Intraperitoneal Application of Taurolidine with Heparin on Subcutaneous and Intraperitoneal Tumor Growth in Laparoscopic Surgery in a Rat Model", <i>Department of Surgery, Humboldt-University of Berlin, Campus Charité Mitte, Schumannstr. 20-21, 10098 Berlin, Germany, April 14th and 15th, 2000, 3 pages.</i>			
	4	CARTER, S., et al. , "Chemotherapy of Cancer", Second Edition, A Wiley Medical Publication, pp. 77-78.			
	5	FOYE, W. , "Cancer Chemotherapeutic Agents", <i>American Chemical Society</i> , Washington, DC, 1995, pp. 50-55.			
	6	JACOBI, C.A., et al. , "Intraperitoneal Instillation of Taurolidine and Heparin for the Prevention of intraperitoneal Tumor Growth and Trocar Metastases in Laparoscopic Surgery in a Rat Model", <i>Langebecks Arch Chir</i> , (1997) 382 Suppl. 1: S31-S36.			
	7	JACOBI, C.A., et al. , "Influence of Different Gases and Intraperitoneal Instillation of Antiadherent or Cytotoxic Agents on Peritoneal Tumor Cell Growth and Implantation with Laparoscopic Surgery in a Rat Model", <i>Surg Endosc</i> , (1999) 13:1021-1025.			
	8	JACOBI, C.A., et al. , "New Therapeutic Strategies to Avoid Intra-and Extraperitoneal Metastases during Laparoscopy: Results of a Tumor Model in the Rat", <i>Dig Surg</i> , 1999; 16:393-399.			
	9	JACOBI, C.A., et al. , "Inhibition of Peritoneal Tumor Cell Growth and Implantation in Laparoscopic Surgery in a Rat Model", <i>The American Journal of Surgery</i> , (1997) Vol. 174, pp.359-363.			
	10	MONSON, J.R.T., et al. , "Preliminary Evidence that Taurolidine is Anti-neoplastic as well as Anti-endotoxin and Anti-microbial", <i>Br. J. Surg.</i> , A711, Vol. 77, No. 6, June 1990.			
	11	MONSON, J.R.T., et al. , "Taurolidine As An Anti-neoplastic Agent: A Previously Undiscovered role?", <i>Br. J. Surg.</i> , 1432, Vol. 77, No. 12, December 1990.			
	12	WEBERCHOCK, T. et al. , "Efficacy of Sytemic Taurolidin Application in the Treatment of Liver Metastases in a Rat Model", <i>Dept. of General and Vascular Surgery, Johann Wolfgang Goethe-University, Frankfurt/Main, Germany</i> , p. 41.			
Examiner Signature				Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.